Article | Open

Isoflurane produces antidepressant effects and induces TrkB signaling in rodents

  • Scientific Reports 7, Article number: 7811 (2017)
  • doi:10.1038/s41598-017-08166-9
  • Download Citation
Received:
Accepted:
Published online:

Abstract

A brief burst-suppressing isoflurane anesthesia has been shown to rapidly alleviate symptoms of depression in a subset of patients, but the neurobiological basis of these observations remains obscure. We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3β (GSK3β). Moreover, isoflurane affected neuronal plasticity by facilitating long-term potentiation in the hippocampus. We also found that isoflurane increased activity of the parvalbumin interneurons, and facilitated GABAergic transmission in wild type mice but not in transgenic mice with reduced TrkB expression in parvalbumin interneurons. Our findings strengthen the role of TrkB signaling in the antidepressant responses and encourage further evaluation of isoflurane as a rapid-acting antidepressant devoid of the psychotomimetic effects and abuse potential of ketamine.

Introduction

Major depression is a highly disabling psychiatric disorder, the most significant risk factor for suicide and one of the biggest contributors to the disease burden worldwide1, 2. Clinical effects of the classical antidepressants appear slowly and many patients respond to them poorly if at all3. Electroconvulsive therapy (ECT) remains the treatment of choice for treatment-resistant depression but repeated ECT produces cognitive side effects. Thus, there is a huge unmet medical need for more efficacious and rapid-acting treatments for major depression.

Discovery of the remarkable rapid antidepressant effect of the N-methyl-D-aspartate receptor (NMDA) blocker ketamine in treatment-resistant patients has inspired renewed enthusiasm towards antidepressant drug development4. However, the psychotomimetic properties and abuse potential limit the clinical use of ketamine5. Emerging evidence suggests that the rapid antidepressant effects of ketamine are mediated by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor dependent fast synaptic transmission and the release of brain-derived neurotrophic factor (BDNF) that further leads to increased signaling of the TrkB-mTOR (mammalian target of rapamycin) pathway, alterations in dendritic spine dynamics, synaptic plasticity and animal behaviour6,7,8. Inhibition of glycogen synthase kinase 3β (GSK3β) is another molecular signaling event recently implicated in the antidepressant mechanisms of ketamine9. These effects set forth by ketamine co-associate with altered GABAergic interneuron function10.

Brief deep isoflurane anesthesia has been shown to produce rapid antidepressant effects in both double-blind and open-label clinical studies11,12,13,14. The clinical observations have been, however, partially inconsistent (see refs 15, 16), which has reduced the interest to thoroughly evaluate isoflurane as an alternative for ECT and ketamine. To this end, we have translated the treatment concept into preclinical settings and evaluated its antidepressant-like and neurobiological effects in rodents. We show that a single isoflurane anesthesia rapidly transactivates TrkB, regulates the mTOR and GSK3β signaling pathways as well as activity and function of GABAergic interneurons, facilitates hippocampal long-term potentiation and produces antidepressant-like behavioural responses in rodents. These findings shed light on the neurobiological basis of clinically observed rapid-acting antidepressant effects of isoflurane and may become instrumental in dissecting shared mechanisms underlying rapid antidepressant responses.

Results

Antidepressant-like behavioural effects of isoflurane in rodents

The rat learned helplessness model (LH) has good face, construct and predictive validity regarding depression17, 18. Whereas long-term treatment with classical antidepressants is required to ameliorate the learned helplessness phenotype18, ketamine produces essentially similar antidepressant-like behavioural effect in the model already after a single treatment19. Consequently, we employed this model to investigate the potential antidepressant-like effects of isoflurane. Indeed, as shown in Fig. 1A, already a single exposure to isoflurane anesthesia produced an antidepressant-like effect (reduced failure to escape from the compartment where the animal receives footshocks) in the LH when the phenotype was assessed at 6 days post-treatment.

Figure 1
Figure 1

A single brief isoflurane anesthesia produces antidepressant-like behavioural effects in rodents (A) A single isoflurane anesthesia (30 min) decreases the escape failures in the learned helplessness test when tested 6 days after the anesthesia (p = 0.0296; n = 7). (B) Mice subjected to right common sciatic nerve cuffing show anxiodepressive behaviour (increased latency to feed) in the novelty suppressed feeding test. Such phenotype is not seen in mice exposed to a single isoflurane anesthesia (30 min) at 12 hours before testing (two-way ANOVA: cuffing*treatment interaction F3,27 = 6,398, p = 0.018; nsham ctrl = 8, nsham iso = 8, ncuff ctrl = 8, ncuff iso = 7). (C) Control and isoflurane-treated mice subjected to the right sciatic nerve cuffing show essentially similar mechanical allodynia in the von Frey test 8-weeks post-surgery (Two-way ANOVA: surgery F1,24 = 123.19, p < 0.001, treatment F1,24 = 0.52, p = 0.47, surgery x treatment interaction F1,24 = 0.006, p = 0.93). The experiment was performed 3 days before and 2 days after control or isoflurane treatment. *p < 0.05, **p < 0.01; Statistical analysis was done using Student’s t test (A) or two-way ANOVA (B, C). Abbreviations: CTRL, control treatment; ISO, isoflurane treatment; Sham, sham surgery; Cuff, cuff surgery; NSF, novelty suppressed feeding test.

Chronic pain is strongly associated with depression20, 21 and previous studies show that persistent neuropathic pain induces behavioural abnormalities typical for depression and anxiety in mice22. Thus, we evaluated the antidepressant-like effects of a single isoflurane anesthesia treatment also in this model. As expected, mice subjected to the sciatic nerve cuffing showed depression-like phenotype (delayed latency to eat food pellet) in the novelty-suppressed feeding (NSF) test at 8-weeks post-surgery (Fig. 1B). Importantly, the phenotype was reversed in the nerve-cuffed animals exposed to isoflurane at 12 hours before the testing (Fig. 1B). The antidepressant-like effects of isoflurane appeared very rapidly in this test compared to classical antidepressants, which require weeks of repeated administration to show similar actions23. Of note, isoflurane did not have antinociceptive effects against the mechanical allodynia produced by the model (Fig. 1C).

Isoflurane anesthesia rapidly activates TrkB receptors

Essentially all antidepressants, including ketamine, have been shown to rapidly, within an hour, activate BDNF receptor TrkB and this effect is proposed to be critically involved in the mechanism of action of antidepressants7, 24,25,26. To test the intriguing possibility that isoflurane might bring about similar responses on TrkB, we subjected adult mice to a brief isoflurane treatment and collected brain samples and assayed the TrkB phosphorylation status. Deep burst-suppressing isoflurane anesthesia (induction 4%, maintenance ~2% ad 30 min; see ref. 27), which is shown to elicit rapid antidepressant effects in patients11, 13, robustly increased the phosphorylation of TrkB (pTrkB) in the medial prefrontal cortex (mPFC) (Fig. 2A), hippocampus (HC) (Fig. 2B) and the somatosensory cortex (Supplementary Figure 1) of adult naïve mice while subanesthetic isoflurane (0.3%) produced no such effects (Fig. 2C). The ability of isoflurane anesthesia to induce pTrkB is extremely fast and transient; a significant increase in pTrkB levels was observed within two minutes from the treatment onset and the TrkB phosphorylation returned close to baseline already at 15 min after the termination of anesthesia (Fig. 2D).

Figure 2
Figure 2

Isoflurane anesthesia induces TrkB autophosphorylation in the brain and produces antidepressant-like effects in the forced swim test. (A,B) Isoflurane anesthesia (30 min) increase phosphorylation of TrkBY816 in the adult mouse medial prefrontal cortex (p = 0.0022) and hippocampus (p < 0.0001). (C) Effect of subanesthetic isoflurane (0.3%, 15 min) on phosphorylation of TrkBY816 in the medial prefrontal cortex. (D) Time-dependent effect of isoflurane anesthesia on TrkB phosphorylation in the medial prefrontal cortex. (E) Significantly increased phosphorylation of the phospholipase-Cγ1 (PLCγ1) binding site (Y816) (p = 0.0182) and the catalytic domain (Y706/7) of TrkB (p = 0.0426) is detected after flag-immunoprecipitation from hippocampus of mice overexpressing flag-tagged full-length TrkB receptors in postnatal neurons. No change is detected in phosphorylation of Shc binding site (Y515) of TrkB (p = 0.8623). (F) Wild-type mice treated with isoflurane for 30 min show reduce immobility in the forced swim test when tested 15 minutes after the end of the treatment, whereas in the mice over-expressing the dominant-negative TrkB.T1 isoform the effect was absent (two-way ANOVA genotype*treatment interaction F3,24 = 4,301, p = 0.049, n = 7). pTrkB levels normalized to total TrkB (AD). Representative western blots (A,B,C,E) have been cropped from complete immunoblots shown in Supplementary Information file. *p < 0.05, **p < 0.01, ***p < 0.001; Mann Whitney U test, Student’s t test, one-way ANOVA followed by Dunnett’s post hoc test (C, all groups compared to the Ctrl) or two-way ANOVA followed by Tukey HSD post hoc test (E). Abbreviations: CTRL, control treatment; ISO, isoflurane treatment; FST, forced swim test; WT, wild-type; T1, mice overexpressing TrkB.T1; PFC, prefrontal cortex; HC, hippocampus.

When transgenic mice over-expressing flag-tagged TrkB in neurons28 were treated with isoflurane, an increase in pTrkB was seen in the flag-antibody precipitated samples (Fig. 2E), demonstrating the specificity of the effect on TrkB. Since the transgene expression in this mouse line is directed to postnatal neurons28, this result also confirms that the pTrkB response takes place in neurons. Isoflurane treatment increased tyrosine phosphorylation of TrkB at the autocatalytic domain (Y706/7) and at the phospholipase-Cγ1 (PLCγ1) binding site (Y816) but not at the Shc binding site (Y515) (Fig. 2E), which is consistent with our previous findings with the classical monoamine-based antidepressants24, 26. Notably, similar changes in pTrkB were also observed after anesthesia with halothane or sevoflurane (Supplementary Figure 2).

TrkB activation is necessary for the antidepressant-like responses to isoflurane in the forced swim test

The forced swim test (FST) is an acute behavioural test used for screening of compounds with antidepressant potential in naïve animals29. Indeed, mice tested 15 minutes after the termination of isoflurane anesthesia showed significantly reduced immobility in the FST compared to sham-treated animals (Fig. 2F). The acute behavioural change produced by isoflurane anesthesia was likely not due to an overall increase in locomotor activity, since isoflurane-treated mice showed reduced rather than enhanced activity in the open field test (Supplementary Figure 3). Importantly, the effects of isoflurane in the FST were absent in mice over-expressing the dominant-negative truncated TrkB.T1 isoform (Fig. 2F). This finding is consistent with the loss of behavioural effects of classical antidepressants in these mice24 and suggests that TrkB is required also for the antidepressant-like effects of isoflurane in the FST.

Isoflurane regulates intracellular signaling implicated in antidepressant responses

Classical antidepressant drugs have been shown to activate the transcription factor cAMP response element binding protein (CREB) downstream of TrkB24, 26. Along with this change, ketamine has been shown to activate protein kinase B (Akt) and mTOR signaling pathways and phosphorylate GSK3β to the inhibitory Ser9 residue6, 7, 9. Ketamine-induced activation of mTOR further leads to phosphorylation and activation of p70S6k and eukaryotic initiation factor 4E binding protein 1 (4E-BP1). Isoflurane anesthesia produced remarkably similar phosphorylation changes on all these intracellular signaling molecules: the phosphorylation levels of CREBSer133, AktT308, mTORS2481, p70S6KT421/S424, 4EBP1T37/46 and GSK3βS9 were significantly increased at 30 minutes after the onset of isoflurane anesthesia in the mouse mPFC (Fig. 3A). Significant phosphorylations of CREBSer133, p70S6KT421/S424, 4EBP1T37/46 and GSK3βS9 were also observed in the HC after 30 min isoflurane treatment, whereas phosphorylation levels of AktT308 and mTORS2481 were not regulated (Fig. 3B). Similarly to the pTrkB response (Fig. 2D), these isoflurane-induced molecular changes were observed within minutes from the treatment onset (Fig. 3C). Collectively these data demonstrate that isoflurane anesthesia very rapidly regulates molecular events intimately associated with rapid antidepressant responses in brain areas implicated in the pathophysiology of major depression.

Figure 3
Figure 3

Isoflurane anesthesia regulates intracellular signaling implicated in rapid antidepressant actions. (A) Phosphorylation of AktT308 (p = 0.0084), CREBS133 (p = 0.0087), mTORS2481 (p = 0.0292), p70S6KT421/S424 (p = 0.0022), 4-EBP1T37/46 (p = 0.0012) and GSK3βS9 (p = 0.0001) in the adult mouse prefrontal cortex after isoflurane anesthesia (30 min). (B) Phosphorylation of AktT308 (p = 0.3052), CREBS133 (p = 0.0014), mTORS2481 (p = 0.7422), p70S6KT421/S424 (p = 0.0022) 4E-BP1T37/46 (p = 0.0022) and GSK3βS9 (p = 0.0001) in the adult mouse hippocampus after isoflurane anesthesia (30 min). (C) Phosphorylation of CREBS133, mTORS2481 and p70S6KT421/S424 are increased within 2 minutes from the onset of isoflurane (4%) administration. pAKT and pCREB levels normalized to corresponding total protein, other phosphoproteins normalized to GAPDH. n = 6/group. Representative western blots have been cropped from complete immunoblots shown in Supplementary Information file. *p < 0.05, **p < 0.01, ***p < 0.001; Student’s t test. Abbreviations: CTRL, control treatment; ISO, isoflurane treatment; CREB, cAMP response element binding protein; Akt, protein kinase B; mTOR, mammalian target of rapamycin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase, GSK3β, glycogen synthase kinase 3β.

Isoflurane transactivates TrkB independently of BDNF and AMPA receptor signaling

Facilitation of AMPA receptor signaling and translation (and release) of BDNF through inhibition of eukaryotic elongation factor 2 (eEF2) are suggested to govern the effects of ketamine on TrkB6, 7, 19, 30, yet we found no clear evidence supporting these mechanisms for isoflurane. First, pretreatment with the AMPA receptor blocker NBQX (10 mg/kg, i.p.) for 10 minutes prior to isoflurane had no effect on the isoflurane-induced TrkB phosphorylation and downstream signaling (Fig. 4A). Moreover, phosphorylation of eEF2 and levels of BDNF (both mRNA and protein) remained unaltered by isoflurane at the time of TrkB phosphorylation (Fig. 4B–D). To investigate the role of BDNF more directly, we performed isoflurane-induced TrkB phosphorylation analyses in mice homozygous for a conditional deletion of BDNF specifically in CaMKII-positive neurons. Importantly, isoflurane readily activates TrkB in the hippocampus of these mice (Fig. 4E) even though the BDNF protein levels are undetectable (Fig. 4D). Notably, essentially similar BDNF-independent acute TrkB (trans)activation has been observed with classical antidepressant imipramine31.

Figure 4
Figure 4

Isoflurane transactivates TrkB. (A) Pre-treatment with the AMPA receptor blocker NBQX (10 mg/kg, i.p.) does not prevent isoflurane (15 min) induced phosphorylations of TrkB (two-way ANOVA: F3,20 = 4.379, p = 0.017; Tukey HSD post hoc test: CTRL vs. NBQX p = 0.972, CTRL vs. NBQX + ISO p = 0.075, CTRL vs. ISO p = 0.050, NBQX + ISO vs. ISO p = 0.996), CREB (two-way ANOVA: F3,20 = 24.731, p < 0.001; Tukey HSD post hoc test: CTRL vs. NBQX p = 0.648, CTRL vs. NBQX + ISO p < 0.001, CTRL vs. ISO p < 0.001, NBQX + ISO vs. ISO p = 1.000) or p70S6K (two-way ANOVA: F3,20 = 6.228, p = 0.0037; Tukey HSD post hoc test: CTRL vs. NBQX p = 0.859, CTRL vs. NBQX + ISO p = 0.041, CTRL vs. ISO p = 0.143, NBQX + ISO vs. ISO p = 0.916). pTrkB normalized to total TrkB, other phospho-proteins to GAPDH. n = 6/group. (B) The phosphorylation of eEF2 was not affected by isoflurane anesthesia (30 min) in the prefrontal cortex. n = 6. Student’s t test. (C) Total Bdnf mRNA (normalized to Gapdh mRNA) levels remain unaltered after isoflurane anesthesia (30 min) (nCtrl = 6; nIso = 5). (D) Mature BDNF protein levels remain unaltered after isoflurane anesthesia (30 min). Analysis done using ELISA and western blot. A representative western blot on right shows the mature BDNF band, which is absent in a sample obtained from conditional BDNF knockout (KO) mouse. (E) Isoflurane anesthesia activates TrkB in the hippocampus of conditional BDNF knockout mice (Two-way ANOVA treatment effect F3,12 = 41,843, p < 0.001; Tukey HSD post hoc test WT CTRL vs. WT ISO p = 0.001, WT CTRL vs. cKO ISO p = 0.015). Representative western blots (A, B, D) have been cropped from complete immunoblots shown in Supplementary Information file. *p < 0.05, **p < 0.01, ***p < 0.001; Abbreviations: CTRL, control treatment; ISO, isoflurane; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NBQX, 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide; CREB, cAMP response element binding protein; eEF2, Eukaryotic elongation factor 2.

Isoflurane does not regulate dendritic spine formation and turnover in the adult mouse cortex

Ketamine has been shown to rapidly – within 24-hours – promote spine recovery in the PFC of stressed rats by enhancing the mTOR-p70S6K signaling pathway6. The ability of isoflurane to readily activate this very same molecular pathway prompted us investigating its effects on dendritic spines 24 hours post-anesthesia. However, the spine densities were not significantly different from that found in the control mice in fixed sections of the PFC, HC or the somatosensory cortex (Fig. 5). Since fixed tissue preparation could undermine changes in spine dynamics, we used in vivo 2-photon time-lapse microscopy to image individual dendritic spines in the same (head-fixed but otherwise freely moving in the Mobile HomeCage32) mouse at 24 hours before (control condition), immediately before and at 24 hours after a brief isoflurane anesthesia. Because the PFC is not easily accessible to in vivo 2-photon imaging, we focused on the somatosensory cortex, where isoflurane also activates the TrkB-p70S6k signaling pathway (Supplementary Figure 1). Spine formation and elimination rates remained unchanged within 24 hours before and 24 hours after isoflurane, indicating that neither spine density nor spine dynamics were significantly affected by isoflurane anesthesia in this region (Fig. 6).

Figure 5
Figure 5

Lack of effects of isoflurane anesthesia on dendritic spines in the mouse cortex and hippocampus. Reconstruction of confocal images showing the medial prefrontal cortex (mPFC) (A and E), the hippocampus (HC) (F) and somatosensory cortex (SSCx) (G) from Thy1-eYFP mice. We analyzed dendritic spine density of the primary apical dendrites of pyramidal neurons in three different segments of 60 µm each up to 180 µm from the cell soma (B; also indicated with *). Representative images of distal dendritic segment between 120 and 180 µm (C). We also analyzed extra-distal dendritic segments in the mPFC and the HC (D; indicated as # in E and F). We analyzed dendritic spine densities from mice subjected to sham or isoflurane treatment (30 min) 24-h before. Histograms showing the densities of spine subtypes in three different segments relative to the distance to the soma (B) in the mPFC (H; indicated as *), HC (I; *) and the SSCx (J; *). Isoflurane treatment did not produce changes to the spine morphology or to the total spine amount at different distances from the soma (2-way ANOVA: treatment effect for distance in the mPFC (F1,36 = 0.7705, p = 0.385), the HC (F1,21 = 1.371, p = 0.2547) and the SSCx (F1,36 = 0.02270, p = 0.8688)). Extra distal segments were also analyzed in the mPFC (H; indicated as #p = 0.6756) and the HC (I; #p = 0.8203). n = 7 mice/group, 3 sections/mouse, 8 dendrites/section. Scale bar in A and D: 4 μm. Statistical analysis was done using Student’s t test (for extra distal segments or # in H and I) and 2-way ANOVA (for the first 180 µm from the cell soma or * in H,I and J).

Figure 6
Figure 6

Effects of isoflurane on dendritic spine turnover in the somatosensory cortex of awake mice. (A) Focal plane showing expression of YFP under the thy1 promoter and the 70 kDa dextran tracer labeled with Texas Red which serves as map to identify the same areas during the different time points of the experiment. (B) Reconstruction of confocal images showing one of the dendritic segments analyzed. (C) Selected area shows a high magnification image of the dendrite to illustrate the spines (C1) 24 hours before, (C2) immediately before and (C3) 24 hours after the isoflurane administration (30 min). White arrowheads indicate stable spines, red arrowhead indicates eliminated spine and blue arrowhead indicates newly formed spine. Histograms represent (D) spine formation (p = 0.6476) and (E) elimination rate (p = 0.7301) before (pre-treatment) and after (post-treatment) isoflurane treatment. n = 3 mice, ~300 spines/mouse were analyzed. Scale bar size corresponds to 60 μm in A, 11.6 μm in B and 3.7 μm in C images. Statistical analysis was done using paired Student’s t test.

A brief isoflurane treatment leads to the facilitation of hippocampal synaptic strength

TrkB signaling importantly regulates neuronal plasticity such as long-term potentiation (LTP)33. Notably, facilitation of LTP has been implicated in the antidepressant response5, 34. We therefore used electrophysiology in acute brain slices from mice treated with isoflurane 24 hours earlier to study field excitatory postsynaptic potentials (fEPSP) recorded in the stratum radiatum of the CA1 region of the HC and evoked by electrical stimulation of the Schaffer collateral pathway. Recordings of input–output relationship showed that isoflurane exposure 24 hours before accentuated basal synaptic transmission in the HC (Fig. 7A). Paired pulse facilitation was not affected by isoflurane implying unaltered release probability and presynaptic function (Fig. 7B). In slices prepared from mice treated with isoflurane 24 hours before, tetanic stimulation (100 Hz/1 s) produced a significantly higher long-term potentiation (LTP) of the fEPSPs than what was seen in the control slices (Fig. 7C) (see ref. 35). These effects of isoflurane on synaptic strength are reminiscent of the previously reported changes seen after a long-term treatment with the classical antidepressant fluoxetine, but they appear much faster36.

Figure 7
Figure 7

Isoflurane accentuates glutamatergic transmission and plasticity in the hippocampus. (A) Slope of field excitatory postsynaptic potential (fEPSP) recorded in the area CA1 plotted as a function of presynaptic fiber volley (PSFV) amplitude recorded in slices from mice treated with isoflurane (30 min) at 24 hours before (n = 12 slices/8 mice) and in control animals (n = 10 slices/7 mice) (one-way ANOVA: F1,20 = 1.314, p = 0.0479). (B) Paired-pulse facilitation induced by two consecutive stimuli with interpulse interval (IPI) between 10 and 200 msec was not different between the groups (F1,10 = 0.354, p = 0.564). n = 9 slices/8 mice for isoflurane group and n = 10 slices/7 mice for control group. Statistical analysis was done using one-way ANOVA. (C) Long-term potentiation (LTP) induced by high-frequency stimulation (HFS, 100 Hz/1 s) is significantly enhanced in slices from isoflurane treated animals (two-way ANOVA: F1,64 = 7.91, p = 0.000896; n = 8 slices/8 mice for isoflurane group and n = 8 slices/7 mice for control group). Representative fEPSPs taken before and 30 min after the HFS are shown in the insets (control = black, isoflurane = grey).

Isoflurane regulates the excitability of parvalbumin-containing interneurons through TrkB

To investigate cellular and network level correlates underlying isoflurane-induced facilitation of synaptic plasticity we performed FosB immunostainings on brain sections with the aim to identify neuronal populations showing sustained activity following isoflurane administration. Interestingly, parvalbumin interneurons within the HC (and cortex; Supplementary Figure 4) showed the most prominent FosB immunoreactivity 24 hours after a brief exposure to isoflurane (Fig. 8A,B). This observation prompted us to test the role of inhibitory interneurons further using pharmacological and genetic tools. Indeed, bath application of picrotoxin essentially abolished the accentuated LTP after isoflurane anesthesia, supporting a GABAA dependent mechanism (Fig. 8C). Moreover, spontaneous inhibitory postsynaptic currents (IPSCs) were significantly increased in CA1 pyramidal neurons in slices obtained from animals treated with isoflurane 24 hours before (Fig. 8D). This effect was due to altered excitability of GABAergic interneurons rather than changes in GABA release, since no difference in miniature IPSCs were detected between control and isoflurane treated mice (Fig. 8E,F). To investigate the potential involvement of TrkB in these effects produced by isoflurane we performed electrophysiological studies in mice with reduced TrkB expression specifically in the parvalbumin interneurons (PV-TrkB+/− heterozygous cKO mice). Importantly, whereas the effect of isoflurane on spontaneous IPSCs was readily recapitulated in hippocampal slices obtained from control animals, such effect was blunted in slices obtained from PV-TrkB+/− mice (Fig. 8G). Altogether these studies suggest that a brief isoflurane anesthesia brings about sustained TrkB dependent changes on the excitability of parvalbumin containing GABAergic interneurons.

Figure 8
Figure 8

Isoflurane treatment leads to an increase in the activity of parvalbumin positive interneurons via activation of TrkB. (A) The intensity of FosB staining in parvalbumin positive (PV+) cells, but not somatostatin positive cells (SOM+) or cells not expressing PV or SOM (PV−/SOM−), is significantly increased in the CA1 area of hippocampus of mice treated with isoflurane 24 hours before (p = 0.0474, Student’s t test). (B) Representative figures of the parvalbumin, somatostatin and FosB stainings. (C) Long-term potentiation (LTP) induced by high-frequency stimulation (HFS, 100 Hz) is enhanced in slices from mice treated with isoflurane for 30 min 24 hours before. The difference between the groups disappears in the presence of picrotoxin (PiX). Representative fEPSPs taken 5 min before and 30 min after the HFS are shown in the insets (control = black, isoflurane = dark grey; control/PiX = light gray; isoflurane/PiX = gray). (D) The average frequency of spontaneous IPSCs in CA1 hippocampal neurons recorded at 24 hours after isoflurane anesthesia (30 min) (6 slices/6 animals per group, ANOVA, p < 0.01) and example traces of the recordings. (E) The average frequency of miniature IPSC in CA1 hippocampal neurons (6 slices/6 animals per group, one-way ANOVA) is not affected by isoflurane treatment. (F) Decay time distribution of mIPSC (6 slices per group, Pearson’s χ2 test). (G) The average frequency and example traces of spontaneous IPSC in CA1 hippocampal neurons recorded 24 h after isoflurane anaesthesia in wild-type (WT) and PV-TrkB+/− heterozygous (KO) mice (WT; 6 slices/6 animals for ISO, 5 slices/5 animals for CTRL; KO - PV-TrkB+/−; 7 slices/7 animals for ISO, 5 slices/5 animals for CTRL; ANOVA, p < 0.05). Abbreviations: CTRL, control treatment; ISO, isoflurane treatment. *p < 0.05, **p < 0.01.

Discussion

Our study shows that isoflurane, at dosing regimen shown to bring about antidepressant effects in clinical studies11, 13, 14, induces TrkB phosphorylation and downstream signaling in the brain regions implicated in antidepressant responses, and that this signaling is accompanied by long-lasting, TrkB dependent plasticity-related physiological and behavioural responses. Previous observations have suggested that the activation of TrkB and subsequent intracellular signaling are required for the behavioural effects of clinically used antidepressants, including the rapid-acting antidepressant ketamine7, 24. The observation that TrkB is also activated by and required for the behavioural effects of isoflurane in the FST strengthens the role for TrkB signaling as the common pathway for antidepressant actions.

While many molecular and cellular mechanisms activated by isoflurane resemble those induced by ketamine, there seem to be important differences in the action of these two drugs. It has been proposed that ketamine facilitates AMPA receptor activation, which subsequently leads to BDNF release and TrkB activation. Our data suggest that isoflurane (and classical antidepressants31) induces TrkB activation without the involvement of BDNF and AMPA receptor activation7. Notably, several neurotransmitters and modulators have been shown to transactivate receptor tyrosine kinases, such as TrkB, through the regulation of Src family kinases37,38,39. Whether such mechanism underlies the isoflurane-induced TrkB activation remains to be investigated. Moreover, isoflurane significantly potentiated glutamatergic synaptic transmission but did not seem to affect synaptic structure (i.e. the morphology and turnover of dendritic spines), while ketamine has been shown to affect both the structure and function of the excitatory synapses6, 30. The lack of effects of isoflurane on dendritic spine dynamics is consistent with previous observations showing that anesthetics, such as isoflurane, significantly regulate dendritic spine number and morphology during brain growth spurt, but not in the adult brain40, 41. Unlike ketamine, however, the effects of isoflurane on dendritic spines have been investigated in animals not subjected to chronic stress. Therefore, the effects of isoflurane and ketamine on molecular signaling events, dendritic spines and neuronal plasticity should be investigated and directly compared in naïve animals and in various animal models of depression (e.g. social defeat stress, chronic unpredictable mild stress). The potential differences in the mechanisms of action between ketamine and isoflurane may become instrumental in the attempts to focus drug discovery efforts towards the pathways activated by both compounds.

Reduced concentration of GABA is implicated in pathophysiology of depression and it has been proposed that many of the currently used antidepressants ultimately act through modulation of GABAergic transmission42, 43. The observation that isoflurane treatment led to changes in the activity of parvalbumin (PV) positive interneurons is consistent with the idea that the primary effect of isoflurane resides in the GABAergic PV interneurons, which regulate the activity of glutamatergic principal neurons via perisomatic inhibition10. Importantly, tetanic stimulation can result in interneuron-driven GABAergic excitation, leading to synchronous spiking in hippocampal pyramidal neurons and thereby promoting LTP induction44, 45.

Remarkably, clinical studies conducted decades ago have shown that isoflurane therapy that induces burst suppressing pattern in the EEG (electroencephalogram) produces a robust and rapid antidepressant response in a subset of treatment-resistant depressed patients11, 13. Although some subsequent trials were unable to replicate these findings15, 16, a recent positive replication by Weeks et al. has renewed the interest towards isoflurane as an antidepressant therapy14. The antidepressant response of isoflurane appears comparable in magnitude to that produced by the ECT, but faster in onset; a significant antidepressant effect was observed after a single isoflurane treatment13. Our current results provide plausible neurobiological basis for the rapid-acting antidepressant efficacy of isoflurane and encourage its further clinical evaluation in depressed patients.

This report has significant implications also outside antidepressant field. Isoflurane is a commonly used anesthetic agent in experimental research. With increased use of electrophysiological, imaging and optogenetic methods requiring surgical operations, mice are often exposed to isoflurane anesthesia prior to behavioural testing. Therefore, the long-lasting physiological and behavioural responses to isoflurane treatment uncovered here should be taken into account when designing and interpreting behavioural assessments in animals previously anesthetized with isoflurane. Given the pronounced effects of anesthetics on several molecular pathways in naïve animals27, the use of anesthesia should be taken into account in experimental research when interpreting the data.

Materials and Methods

Detailed description of Materials and Methods are provided in the Supplementary Information file.

Animals

Adult C57BL/6J, BDNF2L/2LCk-Cre (ref. 46), B6.Cg-Tg(Thy1- YFPH)2Jrs/J, TrkBfl°x/−:PV-Cre+/− (refs 47, 48) heterozygous conditional knockout mice and transgenic mice over-expressing flag-tagged TrkB or truncated TrkB.T128, 49, 50 and their wild-type littermates were used. Adult male Wistar rats were used for learned helplessness test. The learned helplessness studies were conducted in conformity with the Brazilian Council for the Control of Animals under Experiment (CONCEA) and were approved by the local ethical committee of University of São Paulo at Ribeirão Preto campus. The experiments involving neuropathic pain model were performed in accordance with guidelines for animal experimentation of the International Association for the Study of Pain (IASP) and European Communities Council Directive 86/6609/EEC and were approved by the local ethical committee of the University of Strasbourg (CREMEAS, n°AL-04). The experiments involving conditional BDNF mutant mice were performed in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals guidelines and were approved by the Institutional Animal Care and Use Committee at Tufts University. Rest of the experiments were carried out according to the guidelines of the Society for Neuroscience and were approved by the County Administrative Board of Southern Finland (License numbers: ESLH-2007-09085/Ym-23, ESAVI/7551/04.10.07/2013).

In vivo pharmacological treatments

The following drugs were used: isoflurane (inhalation; anesthesia: induction ~4%, maintenance ~1–2%; see ref. 27), sevoflurane (inhalation; anesthesia: induction ~8%, maintenance ~4%), halothane (as for isoflurane) and NBQX (i.p., 10 mg/kg; in saline).

Immunoprecipitation and western blot

The brain samples were homogenized in NP lysis buffer26, centrifuged (16000 g, 15 min, +4 °C) and the resulting supernatant used for analyses. Samples were separated with SDS-PAGE and blotted to PVDF membrane. Membranes were incubated with antibodies directed against phosphorylated or non-phosphorylated forms of Trk/TrkB, CREB, Akt, mTOR, p70S6K, 4E-BP1, GSK3β, eEF2, BDNF and GAPDH. Following consecutive washes and horseradish peroxidase conjugated secondary antibody incubations immunoreactive bands were visualized using enhanced chemiluminescence using a standard camera.

qRT-PCR and ELISA

Total Bdnf mRNA levels were measured using quantitative RT-PCR as described51. BDNF protein levels were analyzed using a commercial ELISA kit.

Spine analysis from fixed tissue

B6.Cg-Tg(Thy1- YFPH)2Jrs/J mice were transcardially perfused with 4% PFA at 24 h after isoflurane/sham treatment under pentobarbital anesthesia. Floating sections (50 μm) were cut using a vibratome and processed for YFP immunofluorescence histochemistry using standard techniques. Images were obtained using confocal microscope and pyramidal neurons from the mPFC and SSCx were selected with the following criteria: intense fluorescence, soma located in layer V, and primary apical dendrite >200 μm long. We imaged the dendrites in three ~65 μm long segments (proximal/medial/distal). We distinguished three types of dendritic spines: (i) stubby; (ii) mushroom and; (iii) filopodia/thin.

In vivo two-photon microscopic imaging in awake mice

B6.Cg-Tg(Thy1- YFPH)2Jrs/J mice and Mobile HomeCage system (Neurotar Ltd., Finland) were used for the analysis of dendritic spine turnover in SSCx (layer 1) in an awake in vivo imaging through cranial window implanted onto the skull above the somatosensory cortex. Five different dendritic segments from 4 different areas were analyzed per animal to study the time-lapse spine turnover52. The spine formation and elimination rates were calculated as the number of spines that have appeared or disappeared, respectively at a given time point compared to the previous time point relative to the total number of spines present at that or the previous time, respectively.

Immunohistochemistry

The tissue was processed as free-floating sections. After blocking and permeabilization the sections were incubated for 48 h at 4 °C with a cocktail containing IgG mouse anti-Somatostatin, IgG guinea pig anti-Parvalbumin and IgG rabbit anti-FosB. After washing the sections were incubated with a cocktail containing the fluorescence conjugated secondary antibodies. Washed sections were mounted on slides and coverslipped using fluorescence mounting medium (Dako).

Electrophysiological recordings

Hippocampal slices (400 μm) were cut with a vibratome as described53. Extracellular recordings from CA1 stratum radiatum were obtained with aCSF (artificial cerebrospinal fluid) filled glass microelectrodes (2–5 MΩ) using an Axopatch 200B amplifier. Field excitatory potentials (fEPSP) were evoked with a bipolar stimulating electrode placed in the Schaffer collateral pathway. LTP was induced by 100-Hz tetanic stimulation for 1 s. The level of LTP was measured as a percentage increase of the fEPSP slope, averaged at a 1-min interval 30 min after the tetanus, and compared to the averaged baseline fEPSP slope. For paired-pulse stimulation, interpulse intervals from 10 to 200 ms were tested. To antagonize fast GABAA synaptic transmission picrotoxin (PiX; 100 µM) was used. WinLTP (0.95b or 0.96, www.winltp.com) was used for data acquisition54. To investigate inhibitory postsynaptic currents, 25 µM MK-801, 5 µM L-689-560 and 20 µM NBQX were included in the aCSF to antagonize NMDA and AMPA receptors. Whole cell voltage clamp recordings (−70 mV) from CA1 neurons were obtained with glass microelectrodes (4.5–6 MOhm) using a Multiclamp 700A amplifier (Axon Instruments, USA). To record miniature IPSCs, 1 µM TTX was added to aCSF. The data analysis was made with Mini Analysis Program, version 5.6.6 (Synaptosoft, USA).

Behavioural tests

Learned Helplessness test

The test was performed as described55. The protocol includes a pre-test session (PT) with 40 unescapable footshocks (0.4 mA, per 10 s) and on the 7th day a test session (T) in which 30 escapable footshocks (0.4 mA, per 10 s) are preceded (5 s) by an alarm tone (60 dB, 670 Hz). In the test session the shock could be interrupted or avoided by the animal if it crosses to the other compartment of the chamber during the tone presentation or during the footshock application. Twenty-four hours after the PT the animals were anesthetized with isoflurane.

Neuropathic pain model of depression

Neuropathic pain was induced by placing a cuff around the main branch of the right sciatic nerve under anesthesia22, 56. Sham-operated mice underwent the same procedure without cuff. The mechanical threshold of hindpaw withdrawal was evaluated using von Frey filaments56, 57. To assess anxiodepressive phenotype the novelty suppressed feeding (NSF) test was done at 12th hour after the isoflurane/sham treatment22, 23.

Forced swim test

A mouse was placed into a glass cylinder (diameter 19 cm, height 24 cm) filled with water (21 ± 1 °C) to the height of 14 cm. Overall immobility was measured during the 6-minute testing period.

Open field test

General locomotor activity was investigated for 30 min in an illuminated (300 lux) transparent cage (length 28.5 × height 8.5 × width 20 cm). Interruptions of infrared photo beams were used to calculate the overall distance traveled (cm).

Statistical analysis

Results are represented as mean ± SEM (standard error of mean) unless otherwise stated. For statistical analysis two-sided tests including unpaired two-tailed Student’s t-test, Mann Whitney U test (non-normally distributed data), one-way analysis of variance (ANOVA), mixed model ANOVA, two-way ANOVA, Pearson’s χ2 test and Spearman’s correlation test were used. Levene’s test was used to define the equality of variances. If the variances differed significantly non-parametric test was used. Post hoc analysis was conducted with Tukey HSD or Dunnett’s test. Statistically significant p value was set to ≤ 0.05. Outliers were considered as values differing more than 2x standard deviation from the mean of the group. To calculate the proper sample sizes we used power calculations (α = 0.05 and power 0.80) and estimated the standard deviations and effect sizes based on our previous experience and literature.

Additional Information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Kessler, R. C. et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA J. Am. Med. Assoc. 289, 3095–3105 (2003).

  2. 2.

    Olesen, J. et al. The economic cost of brain disorders in Europe. Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 19, 155–162 (2012).

  3. 3.

    Fava, M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 53, 649–659 (2003).

  4. 4.

    Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351–354 (2000).

  5. 5.

    Duman, R. S. & Aghajanian, G. K. Synaptic dysfunction in depression: potential therapeutic targets. Science 338, 68–72 (2012).

  6. 6.

    Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964 (2010).

  7. 7.

    Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91–95 (2011).

  8. 8.

    Zanos, P. et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533, 481–486 (2016).

  9. 9.

    Beurel, E., Song, L. & Jope, R. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol. Psychiatry 16, 1068–1070 (2011).

  10. 10.

    Miller, O. H., Moran, J. T. & Hall, B. J. Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: Direct inhibition and disinhibition. Neuropharmacology 100, 17–26 (2016).

  11. 11.

    Langer, G., Neumark, J., Koinig, G., Graf, M. & Schönbeck, G. Rapid psychotherapeutic effects of anesthesia with isoflurane (ES narcotherapy) in treatment-refractory depressed patients. Neuropsychobiology 14, 118–120 (1985).

  12. 12.

    Engelhardt, W., Carl, G. & Hartung, E. Intra-individual open comparison of burst-suppression-isoflurane-anaesthesia versus electroconvulsive therapy in the treatment of severe depression. Eur. J. Anaesthesiol. 10, 113–118 (1993).

  13. 13.

    Langer, G. et al. Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment. A double-blind comparison with electroconvulsive treatment. Neuropsychobiology 31, 182–194 (1995).

  14. 14.

    Weeks, H. R. III et al. Antidepressant and Neurocognitive Effects of Isoflurane Anesthesia versus Electroconvulsive Therapy in Refractory Depression. PLoS ONE 8, e69809 (2013).

  15. 15.

    Greenberg, L. B., Gage, J., Vitkun, S. & Fink, M. Isoflurane Anesthesia Therapy: A Replacement for ECT in Depressive Disorders? Convuls. Ther. 3, 269–277 (1987).

  16. 16.

    García-Toro, M. et al. Inefficacy of burst-suppression anesthesia in medication-resistant major depression: a controlled trial. J. ECT 17, 284–288 (2001).

  17. 17.

    Czéh, B., Fuchs, E., Wiborg, O. & Simon, M. Animal models of major depression and their clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, doi:10.1016/j.pnpbp.2015.04.004 (2015).

  18. 18.

    Cryan, J. F., Markou, A. & Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23, 238–245 (2002).

  19. 19.

    Maeng, S. et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349–352 (2008).

  20. 20.

    Bair, M. J., Robinson, R. L., Katon, W. & Kroenke, K. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 163, 2433–2445 (2003).

  21. 21.

    Attal, N., Lanteri-Minet, M., Laurent, B., Fermanian, J. & Bouhassira, D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain 152, 2836–2843 (2011).

  22. 22.

    Yalcin, I. et al. A time-dependent history of mood disorders in a murine model of neuropathic pain. Biol. Psychiatry 70, 946–953 (2011).

  23. 23.

    Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805–809 (2003).

  24. 24.

    Saarelainen, T. et al. Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects. J. Neurosci. 23, 349–357 (2003).

  25. 25.

    Koponen, E. et al. Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell. Mol. Neurobiol. 25, 973–980 (2005).

  26. 26.

    Rantamäki, T. et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 32, 2152–2162 (2007).

  27. 27.

    Kohtala, S. et al. Brief Isoflurane Anesthesia Produces Prominent Phosphoproteomic Changes in the Adult Mouse Hippocampus. ACS Chem. Neurosci. 7, 749–756 (2016).

  28. 28.

    Koponen, E. et al. Transgenic mice overexpressing the full-length neurotrophin receptor trkB exhibit increased activation of the trkB-PLCgamma pathway, reduced anxiety, and facilitated learning. Mol. Cell. Neurosci. 26, 166–181 (2004).

  29. 29.

    Cryan, J. F. & Mombereau, C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol. Psychiatry 9, 326–357 (2004).

  30. 30.

    Li, N. et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69, 754–761 (2011).

  31. 31.

    Rantamäki, T. et al. Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. PloS One 6, e20567 (2011).

  32. 32.

    Kislin, M. et al. Flat-floored air-lifted platform: a new method for combining behavior with microscopy or electrophysiology on awake freely moving rodents. J. Vis. Exp. JoVE e51869, doi:10.3791/51869 (2014).

  33. 33.

    Castrén, E., & Antila, H. Neuronal plasticity and neurotrophic factors in drug responses. Mol. Psychiatry, doi:10.1038/mp.2017.61 (2017).

  34. 34.

    Castrén, E. & Rantamäki, T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol. 70, 289–297 (2010).

  35. 35.

    Rammes, G. et al. Isoflurane anaesthesia reversibly improves cognitive function and long-term potentiation (LTP) via an up-regulation in NMDA receptor 2B subunit expression. Neuropharmacology 56, 626–636 (2009).

  36. 36.

    Wang, J.-W., David, D. J., Monckton, J. E., Battaglia, F. & Hen, R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J. Neurosci. Off. J. Soc. Neurosci. 28, 1374–1384 (2008).

  37. 37.

    Lee, F. S., Rajagopal, R. & Chao, M. V. Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors. Cytokine Growth Factor Rev. 13, 11–17 (2002).

  38. 38.

    Huang, Y. Z., Pan, E., Xiong, Z.-Q. & McNamara, J. O. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron 57, 546–558 (2008).

  39. 39.

    Rajagopal, R. & Chao, M. V. A role for Fyn in Trk receptor transactivation by G-protein-coupled receptor signaling. Mol. Cell. Neurosci. 33, 36–46 (2006).

  40. 40.

    Briner, A. et al. Volatile anesthetics rapidly increase dendritic spine density in the rat medial prefrontal cortex during synaptogenesis. Anesthesiology 112, 546–556 (2010).

  41. 41.

    Briner, A. et al. Developmental Stage-dependent persistent impact of propofol anesthesia on dendritic spines in the rat medial prefrontal cortex. Anesthesiology 115, 282–293 (2011).

  42. 42.

    Luscher, B., Shen, Q. & Sahir, N. The GABAergic Deficit Hypothesis of Major Depressive Disorder. Mol. Psychiatry 16, 383–406 (2011).

  43. 43.

    Méndez, P., Pazienti, A., Szabó, G. & Bacci, A. Direct alteration of a specific inhibitory circuit of the hippocampus by antidepressants. J. Neurosci. Off. J. Soc. Neurosci. 32, 16616–16628 (2012).

  44. 44.

    Ellender, T. J., Raimondo, J. V., Irkle, A., Lamsa, K. P. & Akerman, C. J. Excitatory effects of parvalbumin-expressing interneurons maintain hippocampal epileptiform activity via synchronous afterdischarges. J. Neurosci. Off. J. Soc. Neurosci. 34, 15208–15222 (2014).

  45. 45.

    Taira, T., Lamsa, K. & Kaila, K. Posttetanic excitation mediated by GABA(A) receptors in rat CA1 pyramidal neurons. J. Neurophysiol. 77, 2213–2218 (1997).

  46. 46.

    Rios, M. et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol. Endocrinol. Baltim. Md 15, 1748–1757 (2001).

  47. 47.

    Hippenmeyer, S. et al. A developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS Biol. 3, e159 (2005).

  48. 48.

    Minichiello, L. et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 24, 401–414 (1999).

  49. 49.

    Saarelainen, T. et al. Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons have impaired long-term spatial memory but normal hippocampal LTP. Synap. N. Y. N 38, 102–104 (2000).

  50. 50.

    Saarelainen, T. et al. Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons show increased susceptibility to cortical injury after focal cerebral ischemia. Mol. Cell. Neurosci. 16, 87–96 (2000).

  51. 51.

    Rantamäki, T. et al. The Impact of Bdnf Gene Deficiency to the Memory Impairment and Brain Pathology of APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease. PLoS ONE 8, e68722 (2013).

  52. 52.

    Chen, J. L. et al. Clustered dynamics of inhibitory synapses and dendritic spines in the adult neocortex. Neuron 74, 361–373 (2012).

  53. 53.

    Pavlov, I., Rauvala, H. & Taira, T. Enhanced hippocampal GABAergic inhibition in mice overexpressing heparin-binding growth-associated molecule. Neuroscience 139, 505–511 (2006).

  54. 54.

    Anderson, W. W. & Collingridge, G. L. Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions. J. Neurosci. Methods 162, 346–356 (2007).

  55. 55.

    Joca, S. R. L., Padovan, C. M. & Guimarães, F. S. Activation of post-synaptic 5-HT(1A) receptors in the dorsal hippocampus prevents learned helplessness development. Brain Res. 978, 177–184 (2003).

  56. 56.

    Bohren, Y. et al. Antidepressants suppress neuropathic pain by a peripheral β2-adrenoceptor mediated anti-TNFα mechanism. Neurobiol. Dis. 60, 39–50 (2013).

  57. 57.

    Yalcin, I. et al. beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann. Neurol. 65, 218–225 (2009).

Download references

Acknowledgements

The authors would like to thank Outi Nikkilä, Nina Karpova, Vootele Võikar, Mikko Airavaara, Jussi Kupari, Yasmin Hohn, Sissi Pastell, Maria Partanen and Virpi Perko for technical assistance. This study has been supported by grants from the European Research Council (iPlasticity, #322742) (E.C.), Sigrid Jusélius Foundation (E.C., T.T.), Academy of Finland (E.C., T.R., T.T.), Orion-Farmos Research Foundation (H.An., S.K.) and Doctoral Program Brain & Mind (H.An.).

Author information

Affiliations

  1. Neuroscience Center, University of Helsinki, P.O. Box 56, Helsinki, FI-00014, Finland

    • Hanna Antila
    • , Maria Ryazantseva
    • , Dina Popova
    • , Pia Sipilä
    • , Ramon Guirado
    • , Samuel Kohtala
    • , Jesse Lindholm
    • , Liisa Vesa
    • , Henri Autio
    • , Mikhail Kislin
    • , Plinio Casarotto
    • , Leonard Khiroug
    • , Sari Lauri
    • , Tomi Taira
    • , Eero Castrén
    •  & Tomi Rantamäki
  2. Division of Physiology and Neuroscience, Department of Biosciences, Faculty of Biological and Environmental Sciences, University of Helsinki, P.O. Box 66, Helsinki, FI-00014, Finland

    • Maria Ryazantseva
    • , Samuel Kohtala
    • , Sari Lauri
    •  & Tomi Rantamäki
  3. Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, FR-67084, Strasbourg Cedex, France

    • Ipek Yalcin
  4. School of Pharmaceutical Sciences of Ribeirão Preto, 14040-903, Ribeirão Preto, São Paulo, Brazil

    • Vinicius Sato
    •  & Sâmia Joca
  5. Tufts University, Boston, MA, USA

    • Joshua Cordeira
    •  & Maribel Rios
  6. Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 66, FI-00014, Helsinki, Finland

    • Tomi Taira

Authors

  1. Search for Hanna Antila in:

  2. Search for Maria Ryazantseva in:

  3. Search for Dina Popova in:

  4. Search for Pia Sipilä in:

  5. Search for Ramon Guirado in:

  6. Search for Samuel Kohtala in:

  7. Search for Ipek Yalcin in:

  8. Search for Jesse Lindholm in:

  9. Search for Liisa Vesa in:

  10. Search for Vinicius Sato in:

  11. Search for Joshua Cordeira in:

  12. Search for Henri Autio in:

  13. Search for Mikhail Kislin in:

  14. Search for Maribel Rios in:

  15. Search for Sâmia Joca in:

  16. Search for Plinio Casarotto in:

  17. Search for Leonard Khiroug in:

  18. Search for Sari Lauri in:

  19. Search for Tomi Taira in:

  20. Search for Eero Castrén in:

  21. Search for Tomi Rantamäki in:

Contributions

H.An., I.Y., E.C. and T.R. designed the experiments, H.An., P.S., M.R., D.P., I.Y., P.C., S.K., R.G., J.L., H.Au., L.V., M.K., V.S., S.J., L.K., T.T., T.R., J.C., S.L., performed the experiments, H.An., D.P., R.G., T.T. performed statistical analyses, H.An., E.C. and T.R. wrote the paper.

Competing Interests

L.K. is a paid employee in Neurotar Ltd.

Corresponding authors

Correspondence to Eero Castrén or Tomi Rantamäki.

Electronic supplementary material

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Creative Commons BY

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.